Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.


Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses a significant unmet medical need for

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

- Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Pruritus of Unknown Origin Expected January/February 2020 - REDWOOD CITY, Calif. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc.

Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

- Pivotal results expected in March/ April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has